IHP Therapeutics

What IHP Therapeutics does

IHP Therapeutics is a privately held, pre-clinical to early clinical-stage biopharmaceutical company headquartered at 930 Brittan Avenue in San Carlos, California. The company is developing a single therapeutic candidate, IHP-102, for the treatment of acute vaso-occlusive crisis in sickle cell disease. Its stated goal is to position IHP-102 as the first self-administered rescue therapeutic for this indication, enabling treatment in the home setting and reducing reliance on costly healthcare facility-based crisis management.

IHP-102 is a novel dual P-selectin and complement inhibitor designed to simultaneously block two key mechanistic drivers of vaso-occlusion in sickle cell disease. By addressing both pathways, the candidate is intended to deliver disease-modifying effects that reduce both acute pain symptoms and progressive tissue and organ damage caused by vaso-occlusive events. The company's broader positioning references a pipeline of glycan therapeutics targeting immune modulation, inflammation, and infection, though the input data only evidences IHP-102 as an active program.

The company operates with a lean team of 1–10 employees and has assembled leadership spanning a President and CEO (Rinko Ghosh, MS, MBA), a Chief Scientific Advisor (John Paderi, PhD), a Board including Vlad Hogenhuis, MD, MBA, and operational leads covering CMC, Program Management, Clinical Operations, and Strategic Sourcing. Clinical and Scientific Advisors include faculty from Emory University School of Medicine and UCSF. As a pre-commercial pharmaceutical company, IHP Therapeutics has no disclosed revenue, no disclosed pricing, no disclosed partnerships, and no disclosed funding rounds in the available data; its go-to-market model is anticipated to involve pharmacy or specialty pharmacy distribution post-regulatory approval.

Name

IHP Therapeutics

Legal name

IHP Therapeutics

Website

https://ihptherapeutics.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

IHP Therapeutics is a private, pre-clinical to early clinical-stage biopharmaceutical company developing IHP-102, a dual P-selectin and complement inhibitor, as the first self-administered rescue therapeutic for acute vaso-occlusive crisis in sickle cell disease patients.

Ownership category

akta.pro rank

Product category

Sickle Cell Disease Therapeutics

NAICS

Ambulatory Health Care Services (621)

SIC

Services-Health Services (8000)

akta.pro primary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

Keywords

• Sickle cell therapeutics
• Glycan therapeutics
• Vaso-occlusive crisis
• Drug development
• Rare disease therapeutics

Headquarters

HQ city

San Carlos

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Marketing channels1 record

Core offering

IHP Therapeutics is developing IHP-102, a novel dual P-selectin and complement inhibitor therapeutic for the treatment of acute vaso-occlusive crisis in sickle cell disease. The drug candidate is intended to be the first self-administered rescue therapeutic, enabling home-based treatment and avoiding reliance on costly and ill-equipped healthcare systems. The company is focused exclusively on this single pre-clinical/early-stage pipeline asset.

Product overview

IHP Therapeutics is a biopharmaceutical company developing a single therapeutic product, IHP-102, for the treatment of acute vaso-occlusive crisis in sickle cell disease. The company is focused exclusively on this one drug candidate, which is a novel dual P-selectin and complement inhibitor designed to be self-administered as a rescue therapeutic, enabling treatment in the home setting rather than requiring hospitalization.

Differentiator

Problem solved

Functional benefit

Products and services

• IHP-102 A novel dual P-selectin and complement inhibitor drug candidate being developed as the first self-administered rescue therapeutic for acute vaso-occlusive crisis in sickle cell disease patients, intended to enable home-based care and avoid costly healthcare system utilization.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Emerging players

• Disc Medicine: Clinical-stage hematology company developing therapeutics for blood disorders including SCD. Comparable as a small, focused rare-hematology biotech navigating similar clinical and regulatory pathways.
• bluebird bio: Developed lovotibeglogene autotemcel, a gene therapy for SCD. Comparable in pursuing disease-modifying approaches for sickle cell, though using a fundamentally different modality.

Direct peers

• Emmaus Life Sciences: Markets Endari (L-glutamine), an FDA-approved therapy to reduce acute complications of SCD. Direct competitor targeting the same patient population and VOC indication.
• Apellis Pharmaceuticals: Commercial-stage biotech with complement inhibitors (Empaveli/Syfovre) targeting complement-mediated disease. Directly comparable on the complement-targeting component of IHP-102's mechanism.
• GlycoMimetics: Clinical-stage company developing glycomimetic small molecules, including rivipansid (a pan-selectin inhibitor) for sickle cell VOC. Closest direct peer to IHP Therapeutics given shared glycan/sugar-based drug chemistry and SCD VOC indication.

Broad incumbents

• CSL Behring: Major hematology and complement-focused biotherapeutics company (e.g., complement modulator portfolio for rare diseases). Comparable on both the hematology commercial infrastructure and the complement-modulator therapeutic approach.
• Vertex Pharmaceuticals: Co-developed and launched Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy approved for sickle cell disease. Comparable in addressing the same SCD population with a high-value, paradigm-shifting therapy.
• Pfizer (Global Blood Therapeutics): Acquired Global Blood Therapeutics, gaining Oxbryta (voxelotor) for SCD. Represents an established commercial player in the same indication whose marketing reach and pricing dynamics would shape IHP-102's commercial landscape.
• Alexion / AstraZeneca Rare Diseases: Established complement-inhibitor franchise (Soliris, Ultomiris, Empaveli). Comparable on the complement-inhibition half of IHP-102's dual mechanism and on rare/hematology commercialization expertise.
• Novartis: Markets Adakveo (crizanlizumab), a P-selectin inhibitor approved for VOC prevention in SCD. Directly comparable mechanism (P-selectin blockade) and indication, making Novartis the most relevant commercial benchmark for IHP-102.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHP Therapeutics